Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.7
4.6
Journals
Pharmaceuticals
Special Issues
Advancements and Challenges of Intrapleural and Peritoneal Drug Delivery
share announcement

Advancements and Challenges of Intrapleural and Peritoneal Drug Delivery

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmaceutical Technology".

Deadline for manuscript submissions: closed (26 April 2024) | Viewed by 3048

Special Issue Editors

Dr. Veria Khosrawipour

E-Mail Website
Guest Editor
Department of Surgery, Petrus-Hospital Wuppertal, 42283 Wuppertal, Germany
Interests: Pleural and Peritoneal surface malignancies; experimental pharmacology; experimental surgery; epidemiology; nanotechnology
Dr. Agata Mikolajczyk-Martinez

E-Mail Website
Guest Editor
Department of Biochemistry and Molecular Biology, University of Environmental and Life Sciences, Wroclaw, Poland
Interests: peritoneal surface malignances; experimental pharmacology; molecular biology of cancer
Dr. Tanja Khosrawipour

E-Mail Website
Guest Editor
Department of Surgery, University-Hospital Düsseldorf, University of Düsseldorf, Düsseldorf, Germany
Interests: peritoneal metastasis; colorectal carcinomas; experimental surgery, surgical oncology, pleural malignancies

Special Issue Information

Dear Colleagues,

Clinically, intracavitary drug delivery systems are gaining more relevance every year. Due to their broad application in a wide range of indications, new and improved concepts are constantly presented and reviewed. These include the management of patients with pleural and peritoneal cancer, malignant effusions, peritonitis, pleuritis or even intraperitoneal dialyses. Significantly, for physicians, these diseases are among the most challenging to treat. For intraperitoneal applications targeting carcinomas, there is a wide range of concepts, including hyperthermic intraperitoneal chemotherapy (HIPEC), Pressurized intraperitoneal chemotherapy (PIPAC), Hyperthermic Nano Aerosol therapy (HINAT), Foam-based intraperitoneal chemotherapy (FBIC) and Gas-based intraperitoneal hyperthermia (GIH) and locoregional nanochemotherapy.

Nevertheless, these applications consist of fundamental theories and concepts which may extend to various other body cavities (i.e., the pleural cavity). However, they may also show efficacy in other clinical indications such as intraperitoneal dialyses, peritonitis, pleuritis and the management of malignant pleural effusions. This special edition includes basic as well as advanced concepts of intraperitoneal and pleural drug delivery and covers new developments and management of intraperitoneal and pleural applications.

We especially welcome original articles, case reports and short commentaries on:

  • Peritoneal and pleural drug delivery
  • Concepts of drug delivery (intracavitary)
  • Pharmacological and molecular biological studies with regard to pleural and peritoneal cavity
  • Clinical studies and animal experiments
  • Electron microscopy studies on drug particles for intracavitary delivery
  • Applications related to intraperitoneal and pleural treatments pharmacological and toxicological studies

Dr. Veria Khosrawipour
Dr. Agata Mikolajczyk-Martinez
Dr. Tanja Khosrawipour
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • peritoneal and pleural malignancies
  • intraperitoneal and pleural drug delivery
  • peritoneal dialyses
  • peritonitis, pleuritis
  • hyperthermic intraperitoneal chemotherapy (HIPEC)
  • surface applications
  • colorectal cancer
  • ovarian cancer

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 4466 KiB  
Article
First In Vivo Applicational Data of Foam-Based Intrathoracic Chemotherapy (FBiTC) in a Swine Model
by Carolina Khosrawipour, Jakub Nicpoń, Zdzisław Kiełbowicz, Przemysław Prządka, Bartłomiej Liszka, Kacper Zielinski, Veria Khosrawipour, Shiri Li, Hien Lau, Joanna Kulas, Agata Diakun, Wojciech Kielan, Agata Mikolajczk-Martinez and Mariusz Chabowski
Pharmaceuticals 2024, 17(1), 45; https://doi.org/10.3390/ph17010045 - 27 Dec 2023
Viewed by 870
Abstract
Background: For decades, both intraperitoneal and pleural chemotherapy (IPC) have been delivered as a liquid solution. Recent studies suggest that foam carriers outperform liquid carriers for locoregional chemotherapy. For the first time, this study aims to evaluate the feasibility, safety, and characteristics of [...] Read more.
Background: For decades, both intraperitoneal and pleural chemotherapy (IPC) have been delivered as a liquid solution. Recent studies suggest that foam carriers outperform liquid carriers for locoregional chemotherapy. For the first time, this study aims to evaluate the feasibility, safety, and characteristics of foam-based intrathoracic chemotherapy (FBiTC) in an in vivo setting. Methods: In this study, contrast-enhanced FBiTC with doxorubicin was delivered via video-assisted thoracoscopy (VAT) in three swine under general anesthesia. Intraoperative and postoperative parameters, blood analyses, vital signs, and anesthesiologic data were collected. Additionally, an intraoperative computer tomography (CT) scan was performed, and histological tissue sections were collected and further analyzed using fluorescence microscopy. Results: FBiTC was delivered without major complications. End-tidal capnometry detected increased CO2 levels with reduced peripheral oxygen saturation and increased blood pressure and heart rate. No major intra- or postoperative complications were observed. CT scans confirmed a multidirectional distribution pattern of foam. Postoperative laboratory workup did not reveal any critical changes in hemoglobin, white blood count, or platelets. There was no evidence of critical kidney impairment or liver function. Fluorescence microscopy of tissue specimen detected doxorubicin in pleural tissues. Discussion: Our preliminary results are encouraging and indicate that FBiTC is feasible. However, to consider a possible clinical application, further studies are required to investigate the pharmacologic, pharmacodynamic, and physical properties of FBiTC and to ensure the safety of the overall procedure regarding oxygenation levels and capnography parameters. Full article
(This article belongs to the Special Issue Advancements and Challenges of Intrapleural and Peritoneal Drug Delivery)
►▼ Show Figures

Figure 1

12 pages, 1856 KiB  
Article
Triple-Therapy of Peritoneal Metastasis—Partial-Dehydration under Hyperthermic Condition Combined with Chemotherapy: The First Preliminary In-Vitro Results
by Carolina Khosrawipour, Agata Diakun, Shiri Li, Hien Lau, Joanna Kulas, Veria Khosrawipour, Wojciech Kielan and Agata Mikolajczyk-Martinez
Pharmaceuticals 2023, 16(5), 763; https://doi.org/10.3390/ph16050763 - 18 May 2023
Cited by 1 | Viewed by 1485
Abstract
A newly introduced combination of intraperitoneal dehydration and hyperthermia has recently been shown to be feasible and cytotoxic for colon cancer cells in vivo. For the first time, our study now aims to evaluate dehydration under hyperthermic conditions combined with chemotherapy for potential [...] Read more.
A newly introduced combination of intraperitoneal dehydration and hyperthermia has recently been shown to be feasible and cytotoxic for colon cancer cells in vivo. For the first time, our study now aims to evaluate dehydration under hyperthermic conditions combined with chemotherapy for potential use in the clinical setting. In this study, in vitro colon cancer cells (HT-29) were subjected to single or several cycles of partial dehydration under hyperthermic conditions (45 °C), followed by chemotherapy (triple exposure) with oxaliplatin or doxorubicin in various configurations. The viability, cytotoxicity, and proliferation of cells after the proposed protocols were assessed. Intracellular doxorubicin uptake was measured via flow cytometry. After one cycle of triple exposure, the viability of HT-29 cells was significantly reduced versus the untreated control (65.11 ± 5%, p < 0.0001) and versus only chemotherapy (61.2 ± 7%, p < 0.0001). An increased chemotherapeutic inflow into the cells after triple exposure was detected (53.4 ± 11%) when compared to cells treated with chemotherapy alone (34.23 ± 10%) (p < 0.001). Partial dehydration in a hyperthermic condition combined with chemotherapy increases the overall cytotoxicity of colon cancer cells significantly compared to chemotherapy alone. This could possibly be related to enhanced intracellular uptake of chemotherapeutic agents after partial dehydration. Further studies are required for the further evaluation of this new concept. Full article
(This article belongs to the Special Issue Advancements and Challenges of Intrapleural and Peritoneal Drug Delivery)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop